ACSF3

Across TCGA pan-cancer cohorts, ACSF3 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of ACSF3’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ACSF3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ACSF3 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and PDAC are the cancer types where ACSF3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ACSF3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−1.107	<.001	12	view →
HNSC	All	II,III,IV	−0.136	.005	6	view →
PDAC	Female	II,III,IV	−0.305	.002	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

ACSF3–CCRCC

Open the CCRCC breakdown →